Directly observed therapy prior to ambulatory blood pressure measurement (DOT-HTN) in uncontrolled hypertensive patients - Effect on blood pressure, safety and patient perception

References

• Burnier M. Vrijens B. Taxonomy of medication adherence: recent developments. In: Burnier M, editor. Drug adherence in hypertension and cardiovascular protection. Cham, Switzerland: Springer International Publishing AG part of Springer Nature; 2018. p. 1–8.
   Google Scholar
• Eskas PA, Heimark S, Eek Mariampillai J, et al. Adherence to medication and drug monitoring in apparent treatment-resistant hypertension. Blood Press. 2016;25(4):199–205.
   PubMed Web of Science ®Google Scholar
• Gundersen POM, Helland A, Spigset O, et al. Quantification of 21 antihypertensive drugs in serum using UHPLC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2018;1089:84–93.
   PubMed Web of Science ®Google Scholar
• Tomaszewski M, White C, Patel P, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart. 2014;100:855–861.
   PubMed Web of Science ®Google Scholar
• Jung O, Gechter JL, Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31:766–774.
   PubMed Web of Science ®Google Scholar
• Ceral J, Habrdova V, Vorisek V, et al. Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res. 2011;34:87–90.
   PubMed Web of Science ®Google Scholar
• Brinker S, Pandey A, Ayers C, et al. Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension. J Am Coll Cardiol. 2014;63:834–835.
   PubMed Web of Science ®Google Scholar
• Chung O, Vongpatanasin W, Bonaventura K, et al. Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension. J Hypertens. 2014;32:2411–2421.
   PubMed Web of Science ®Google Scholar
• Pandey A, Raza F, Velasco A, et al. Comparison of Morisky Medication Adherence Scale with therapeutic drug monitoring in apparent treatment-resistant hypertension. J Am Soc Hypertens. 2013;9:420–426.e2.
   Web of Science ®Google Scholar
• Strauch B, Petrak O, Zelinka T, et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens. 2013;31:2455–2461.
   PubMed Web of Science ®Google Scholar
• World Health Organization [Internet]. WHO Tuberculosis Programme; Framework for effective tuberculosis control; 1994 [cited 2016 May 2]. Available from: http://apps.who.int/iris/bitstream/10665/58717/1/WHO_TB_94.179.pdf.
   Google Scholar
• Fadl Elmula FE, Hoffmann P, Fossum E, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension 2013;62:526–532.
   PubMed Web of Science ®Google Scholar
• Hjørnholm U, Aamodt M, Larstorp AC, et al. Directly Observed Therapy in Hypertension (DOT-HTN). In: Burnier M, editor. Drug adherence in hypertension and cardiovascular protection. Cham, Switzerland: Springer International Publishing AG part of Springer Nature; 2018. p. 57–85.
   Google Scholar
• Williams B, Mancia G, Spiering W, et al. Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Blood Press. 2018;27:314–340.
   PubMed Web of Science ®Google Scholar
• Randomization.com [Internet]. [cited 2015 Feb 15]. Available from: http://www.randomization.com/.
   Google Scholar
• Fadl Elmula FE, Hoffmann P, Larstorp AC, et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension 2014;63:991–999.
   PubMed Web of Science ®Google Scholar
• Haynes M, Patterson DG. Experimental development of the graphic rating method. Psychol Bull. 1921;18:98–99.
   Google Scholar
• Freyd M. The graphic rating scale. J Educ Psycol. 1923;14:83–102.
   Google Scholar
• Bender A, Peter E, Wynn F, et al. Welcome intrusions: an interpretive phenomenological study of TB nurses’ relational work. Int J Nurs Stud. 2011;48:1409–1419.
   PubMed Web of Science ®Google Scholar
• Hjemdahl P. Ethical aspects of measuring adherence to antihypertensive treatment. In: Burnier M, editor. Drug adherence in hypertension and cardiovascular protection. Cham (Switzerland): Springer International Publishing AG part of Springer Nature; 2018. p. 99–104.
   Google Scholar
• World Health Organization [Internet]. Adherence to long-term therapies: evidence for action. Geneva: WHO; 2003 [cited 2016 May 2]. Available from: http://www.who.int/chp/knowledge/publications/adherence_report/en/.
   Google Scholar
• Checchi KD, Huybrechts KF, Avorn J, et al. Electronic medication packaging devices and medication adherence: a systematic review. JAMA 2014;312:1237–1247.
   PubMed Web of Science ®Google Scholar
• Morisky DE, Ang A, Krousel M, et al. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertension. 2008;10:348–354.
   PubMed Web of Science ®Google Scholar
• Stewart K, George J, Mc Namara KP, et al. A multifaceted pharmacist intervention to improve antihypertensive adherence: a cluster-randomized, controlled trial (HAPPy trial). J Clin Pharm Ther. 2014;39:527–534.
   PubMed Web of Science ®Google Scholar
• Berben L, Bogert L, Leventhal ME, et al. Which interventions are used by health care professionals to enhance medication adherence in cardiovascular patients? A survey of current clinical practice. Eur J Cardiovasc Nurs. 2011;10:14–21.
   PubMedGoogle Scholar
• Heimark S, Eskas PA, Mariampillai JE, et al. Tertiary work-up of apparent treatment-resistant hypertension. Blood Press. 2016;25(5):312–318.
   PubMed Web of Science ®Google Scholar
• Miriampillai JE, Eskas PA, Heimark S, et al. Apparent treatment-resistant hypertension – patient-physician relationship and ethical issues. Blood Press. 2017;26:133–138.
   PubMed Web of Science ®Google Scholar
• Hameed MA, Tebbit L, Jacques N, et al. Non-adherence to antihypertensive medication is very common among resistant hypertensives: results of a directly observed therapy clinic. J Hum Hypertens. 2016;30:83–89.
   PubMed Web of Science ®Google Scholar
• Zarowitz BJ, Stebelsky LA, Muma BK, et al. Reduction of high-risk polypharmacy drug combinations in patients in a managed care setting. Pharmacotherapy. 2005;25:1636–1645.
   PubMed Web of Science ®Google Scholar
• Linicus Y, Kindermann I, Helfer AG, et al. Witnessed drug intake before planned denervation–always harmless? Int J Cardiol. 2015;179:125–126.
   PubMed Web of Science ®Google Scholar
• Burnier M, Wuerzner G, Struijker-Boudier H, et al. Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension 2013;62:218.
   PubMed Web of Science ®Google Scholar